This promotional material is intended for UK Healthcare Professionals (HCPs) experienced in the diagnosis and management of Parkinson’s disease only. Adverse event reporting can be found below
PRODUODOPA is indicated for the treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combination of Parkinson’s medicinal products have not given satisfactory results.1,2
Because levodopa may activate malignant melanoma, PRODUODOPA should not be used in patients with suspicious undiagnosed skin lesions or a history of melanoma.
PRODUODOPA is indicated for the treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combination of Parkinson’s medicinal products have not given satisfactory results.1,2
Because levodopa may activate malignant melanoma, PRODUODOPA should not be used in patients with suspicious undiagnosed skin lesions or a history of melanoma.
Some patients may not be suitable for PRODUODOPA. You are strongly advised to read the Prescribing information (PI), and Summary of Product Characteristics (SmPC) for Great Britain (GB) or Northern Ireland (NI) which can be found via the links above, to evaluate patient suitability for PRODUODOPA.
Now they can have more ‘ON’ time without troublesome dyskinesia compared to oral immediate-release (IR) levodopa/carbidopa at 12 weeks3
The first subcutaneous continuous levodopa-based therapy for patients with advanced Parkinson’s disease1,2
PRODUODOPA (foslevodopa/foscarbidopa) 240 mg/12 mg per ml solution for infusion is a prodrug combination of levodopa monophosphate and carbidopa monophosphate (ratio 20:1) in a solution for 24 hour/day continuous subcutaneous infusion in advanced Parkinson’s disease patients who are not adequately controlled with current medical therapy.1,2
Foslevodopa and foscarbidopa are converted in‑vivo to levodopa and carbidopa.1,2
Because levodopa may activate malignant melanoma, PRODUODOPA should not be used in patients with suspicious undiagnosed skin lesions or a history of melanoma.
NICE RECOMMENDATION
Foslevodopa–foscarbidopa is recommended as an option for treating advanced levodopa-responsive Parkinson’s in adults whose symptoms include severe motor fluctuations and hyperkinesia or dyskinesia, when available medicines are not working well enough, only if:4
- They cannot have apomorphine or deep brain stimulation, or these treatments no longer control symptoms, and
- The company provides foslevodopa–foscarbidopa according to the commercial arrangement
Link will take you to a third party website, not controlled by Abbvie.
CLINICAL DATA
PRODUODOPA efficacy and safety data from the 12 and 52 week studies3,5
SAFETY
Read safety information including adverse events for PRODUODOPA
DOSING AND ADMINISTRATION
Learn about the dosing and administration of PRODUODOPA
Please refer to the PRODUODOPA Summary of Product Characteristics (SmPC) for further information on adverse events, contraindications and special warnings and precautions for use.
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
Adverse events should also be reported to AbbVie on [email protected]
UK-PRODD-230027. Date of preparation: December 2023.
